

IFPF 2026

11th IP Forefront Pharma Forum

Innovation, Protection, Globalization – A New Ecosystem for Pharma IP



Sept 16-18 2026

The Longemont Hotel Shanghai China

IFPF 2026 Will Help You Understand:

- Observation and Development of Drug PTE and Test Data Protection
- Frontiers and Challenges of Second Medical Use Patent Protection
- New IP Landscape of Conjugate Drugs (ADC/RD-C/Small Nucleic Acid)
- Golden Window for Biosimilar Going Global (Patent Expiry Wave 2025-2034)
- Definition of the Scope of Protection of Crystalline Patent Claims (Divergence Between the Indobufen Case and the Topiroxostat Case)
- Comparison of Pharma Patent Equivalent Infringement from the Perspective of Sino-US Judicial Practice
- Administrative Adjudication and Judicial Litigation in the Early Resolution Mechanism of Pharma Patent Disputes
- In-depth Comparison of Pharma Patent Examination and Grant Standards in China, the US and Europe
- Hot Issues in US Patent Drafting and Prosecution – New Trends in Pharma Patent Drafting, Examination and Reexamination
- Situation of Pharma Cases Before the Unified Patent Court (UPC)
- Amendments to the New Edition of the EPC Guidelines for Examination and Suggestions for Patent Drafting
- IP Challenges and Responses in AI-Driven Drug Discovery, and IP System Construction Under MNC Thinking



IFPF 2026 Brings Together

- Patent Attorneys
- Government Representatives
- In-House Counsel and Legal Directors, BD Heads and Managers, In-House R&D Director/Managers
- Heads/Directors of Patents, Patent Counsel and Patent Managers
- Heads/Directors of IP, IP Counsel and IP Managers
- Attorneys specializing in IP and Patent Litigation and Patent Specialists/Experts



IFPF 2026 Highlights

(The Most Compelling Reasons to Attend)

- 100+** Eminent speakers sharing their Insights and practices in different jurisdictions
- 400+** Domestic and foreign drugmakers (Including scientific research institutions)
- 80+** Leading law firms and IP agencies from local and abroad
- 500+** In-house Pharma IP counsel, patent prosecutors and litigators, government officials and policy experts
- 20+** Hours networking opportunities during this 3 days conference (Tea break, three days lunch for all participants)



Deep Topic



Pharma Focus



Diverse Perspectives



Chasing Perfection



6+
Pre-Conference Seminar



100+
Speakers



500+
Attendees



20+
Countries / Regions

Organizer



Diamond Sponsor



Platinum Sponsor




Gold Sponsor



Silver Sponsor



Exhibition Sponsor



Lanyards Sponsor




Gift Supporter

Pre-Conference Seminar A:
PTE, RDP and Patent Linkage

- 

Yongshun Cheng (Chair)
Former Deputy Head of IP Division
Beijing High People's Court
- 

Frank Zhu (Discussion Speaker)
VP Patent China
Roche
- 

Feng Xu (Discussion Speaker)
International Chief IP Counsel
AstraZeneca
- 

Lifang Sun (Discussion Speaker)
IP Vice President
Luye Pharma Group
- 

Tony Chen (Discussion Speaker)
Partner
Jones Day
- 

Li Wu (Discussion Speaker)
Partner
Lifang & Partners

Panel 1: Current Status and Issues of China's
Pharmaceutical Patent Linkage System

Current status and issues of China's pharmaceutical patent linkage system, with case studies and industry concerns.

- Hot topics in patent linkage-related cases
- The "safe harbor" effect of Type III declarations – does it circumvent the purpose of the system?
- Should Type III declarations be included in the scope of the early resolution mechanism for patent disputes?
- First-generic market exclusivity and system coordination
- Patent information registration platform: registration standards and correction mechanisms

10:40 Coffee Break

Panel 2: PTE + RDP Dual-Track Synergy -
Top-Level Design for Patent and Data
Exclusivity in China's Pharmaceutical Industry

China's unique "registration classification threshold" under the PTE system effectively excludes most drugs other than "global new" products from eligibility for compensation. For both multinational and local innovative pharmaceutical companies, the critical question is how to maximize the use of China's PTE system through coordinated patent, regulatory, and clinical strategies, while avoiding the pitfalls exemplified by the semaglutide case. Meanwhile, the Drug Test Data Protection (RDP) regime, as a parallel institutional tool to PTE, offers a six-year exclusivity period that can be arranged sequentially or cumulatively with PTE, thereby establishing a dual-layer defense combining "patent barriers" and "data barriers." Given that the two systems differ in eligibility requirements, triggering events, and scope of protection, the core challenge lies in achieving synergy rather than misalignment in top-level strategic design.

- Eligible patent types
- Eligible drug categories
- Exclusion dilemmas for Category 5.1 and Category 3.1 drugs
- Issues concerning a single patent covering multiple drugs
- Calculation formula for the compensation period
- Scope of protection during the compensation period
- Latest developments in drug test data protection (including the scope of RDP-eligible products, the starting point for the six-year exclusivity period, and the temporal interface with PTE)
- Clinical strategy: embedding "China-synchronized" development into the global R&D roadmap
- Patent strategy: establishing a dynamic screening mechanism for PTE-eligible patents
- Combination strategy: synergistic overlap of PTE and RDP (including pathways where RDP first establishes a data exclusivity period, followed by PTE to extend the patent protection term in a sequential manner)
- Insights from the Case of Bayer's Finerenone Successfully Obtaining the Maximum 5-Year PTE Compensation

12:40 Buffet Lunch (2F ,O2on2)

Pre-Conference Seminar B:
Opportunities and Challenges for
China Biotech

- 

Xun Yang (Chair)
Partner
Links Law Offices
- 

Qian Ma
Biopharma IP Director
Simcere Pharmaceutical

Cross-Border BD IP Risk Management Through
the Lens of the "Blockbuster" Century
Litigation: A Deconstructive Analysis of IP
Strategy and Legal Nuances in the Enhertu Case

Although the seven-year "century patent litigation" surrounding the new-generation blockbuster drug Enhertu has now come to a close, the cross-border mega-disputes it triggered have sounded a resounding alarm for the industry on intellectual property risk management. This presentation will provide a comprehensive retrospective of the multi-dimensional strategic maneuvers and risk exposures of Daiichi Sankyo, Seagen, and AstraZeneca throughout this case. Drawing on the latest U.S. legal standards for determining the validity of continuing patent applications, this talk will conduct an in-depth deconstruction of the underlying contest between the two core dimensions—IP strategy and legal nuances. At the same time, it will bring the focus back to the frontline of cross-border pharmaceutical BD transactions, sharing practical guidelines for building robust IP risk prevention frameworks. The ultimate goal is to counterbalance macro-level commercial uncertainty with micro-level legal certainty, thereby safeguarding the global voyage of China's innovative pharmaceutical industry.

- 

Lu Xiao
Head of Foreign-related Legal Affairs
A-share Listed Pharmaceutical Company

IP Due Diligence for China-Origin Therapeutic
Assets in Cross-Border Transactions

About half of molecules that large pharma and new biotech companies licensed in recent deal cycles came from Asia, especially China. Yet many IP risks in these deals are unique to China or different from US/EU practice, and early gaps can hit valuation, enforceability, and exit potential.

- Key IP ownership, inventorship, and compliance issues that US acquirers and licensees look for during due diligence
- How to build a "diligence-ready" patent portfolio that maximizes deal valuation
- Common pitfalls in cross-border patent filings (foreign filing licenses, inventorship standards, priority chain management, etc.)
- Freedom-to-operate (FTO) best practices before engaging with potential partners
- Lessons from recent IP diligence on billion-dollar China-origin therapeutic assets

- 

Mi Cai
U.S. Patent Attorney
Foley Hoag LLP

10:30 Coffee Break

What do Chinese Biotech Companies Expect
from IP Today?

- 

Dr. Yishu Huang
Partner
Beshining law firm

Panel: The Triangular Link of BD, Financing
and NewCo – How IP Drives Corporate Value
Maximization

- What role has IP played in transaction pricing during the 2025-2026 BD boom? How has that changed from previous years?
- What reusable IP experiences have been gained from Kailera's successful IPO and Ouro Medicines' successful exit for subsequent NewCo deals?
- IPO reviews increasingly demand “technological independence” of IP assets – how should companies build an end-to-end IP management system covering R&D records, patent portfolio, and FTO?
- As financing environment warms, how can IP departments collaborate with CFOs and BD teams to convert IP value into enterprise valuation recognized by capital markets?

- 

Xun Yang (Chair)
Partner
Links Law Offices
- 

Yu Wu
Partner SH Office
JunHe
- 

Ming Liu
IP Head
MediLink Therapeutics
(Suzhou) Co., Ltd.
- 

Lu Xiao
Head of Foreign-related
Legal Affairs
A-share Listed Pharmaceutical
Company

12:40 Buffet Lunch (2F ,O2on2)

Pre-Conference Seminar C
Frontiers and Challenges of Second Medical Use Patents

- 

Fei Wang (Chair)
Sr. IP Director
Lepu Biopharma

Insights into Landmark Cases: The Evolution
of Legal Boundaries and Review Logic

- 

Lili Cao
Partner
LIU SHEN & ASSOCIATES

Trends in U.S. and EU Examination of Medical
Use Patents

- 

Xinmeng Fan
IP Director
Conova Pharmaceutical

The Protection Dilemma for Dosage/Regimen
Medical Use Inventions

New indication-type inventions have a relatively mature protection path, but dosage/regimen-type inventions (dose, frequency, sequence, combination regimens, etc.) remain in a grey area. Is this imbalance justified? Should the technical contribution of dosage/regimen inventions (often relying on high-cost, long-cycle clinical studies) receive a higher level of protection?

- 

Fei Wang
Sr. IP Director
Lepu Biopharma

10:30 Coffee Break

Claim Drafting Strategies for Medical Use
Patents

Facing the narrow interpretation of “manufacturing process” and the forced “drug-pack” construction, how to maximize the scope of protection through claim design? This session will discuss drafting practices for combination therapies, dosage regimens, etc., including design-arounds, divisional strategies, and the appropriate level of disclosure in the specification, providing actionable layout ideas for companies.

- 

Dr. Kezheng Peng
Senior Patent Agent, Attorney at law
Han Kun Law Offices

Panel: International Experience and China's
Path for Second Medical Use Patent Protection

- Latest practices of the UPC on infringement determination for second medical use patents
- Tightening trend of US examination on obviousness of dosage regimen patents
- How can China's medical use patent system forge a suitable development path amid international trends?
- Second medical use and features of dosage regime and patient group in Brazil, an insight into public consultation and open debate with the Brazilian Patent Office

- 

Sunny Wang (Chair)
CEO
SR Biomedical
- 

Xiaojun Liao
Sr. IP Director
Nanjing Legend
Biotechnology
- 

Gustavo Morais
Partner
Dannemann Siemsen
- 

Lin Lv
Deputy Director of IP
Kelun-Biotech
- 

Jiwei Yin
Deputy GM
Beijing Sino-Creativity
Intellectual Property Law Firm

12:40 Buffet Lunch (2F ,O2on2)

Pre-Conference Seminar D:
New IP Landscape for Conjugate Drugs

 **Lily Wang (Chair)**
Founder
Bioipolaris

14:00

Preliminary Exploration of Patent Portfolio Strategy for Bispecific Antibodies

Bispecific antibodies, due to their unique dual-targeting mechanism and broad clinical application prospects, have become a hotspot in global biopharmaceutical R&D. As both domestic and international companies intensively build their presence in this space, patent competition in the bispecific antibody field has become increasingly fierce, with IP barriers and risks rising in parallel.

 **Aiyao Zhan**
IP Director
Hangzhou Bio-Sincerity Pharma-Tech

14:30

Fighting Equivalence in Europe

 **Michael Bech Sommer**
Partner, European Patent Attorney
AWA

15:00

Global Patent Layout Strategy for Conjugated Drugs from the Perspective of BD Transactions

 **Jian Yang**
Partner
Lifang & Partners

15:30 Coffee Break

16:00

Analysis of Patent Technologies for Small Nucleic Acid Conjugate Delivery

 **Wei Gao**
Chief IP Officer
Yaojing Gene

16:30

Panel: Offensive and Defensive Games in Conjugate Drug Patents – From Tri-Regional Examination Practices to Overseas Litigation Risks

What substantive differences exist among CNIPA, USPTO and EPO regarding enablement of broad functional claims for conjugate drugs?

- US Seagen v. Daiichi case
- UPC litigation risks and Chinese companies’ preparedness
- Potential divergence between UPC and EPO on validity of conjugate drug patents

 **Lily Wang (Chair)**
Founder
Bioipolaris

 **Mi Cai**
U.S. Patent Attorney
Foley Hoag LLP

 **Michael Bech Sommer**
Partner, European Patent Attorney
AWA

 **Edit Szodorai**
European Patent Attorney
AWA

18:00

End of Pre-Conference Seminars

 18:10
Cocktail Reception
Dragon Ballroom B, 6F (Open to all participants)

Pre-Conference Seminar E:
IP Strategies for Pharma Global Expansion

 **Meng Wang (Chair)**
Deputy GM
Beijing Taya IP Consultancy Ltd

14:00

Industry Practice: IP and Strategy for Biosimilar Global Expansion

From 2025 to 2034, dozens of blockbuster biologic patents with annual sales exceeding US\$1 billion will expire one after another – a golden window for Chinese biosimilars to go global.

 **Daisy Wu**
IP Director
Shanghai Henlius Biotech, Inc.

14:30

IP Portfolio for Cell Therapy Global Expansion

Homegrown CAR-T products have successfully entered the US and European markets, and local companies’ European patents have withstood challenges. Differences in examination standards among CNIPA, USPTO and EPO, together with FTO analysis and patent portfolio strategies, are critical.

 **Dr. Ryan Hagglund**
Partner
Loeb & Loeb LLP

15:00

The New Ecosystem of Pharmaceutical Intellectual Property in China: Policy Implementation and Strategic Restructuring Amid the Changing Landscape of Global Expansion

 **Meng Wang**
Deputy GM
Beijing Taya IP Consultancy Ltd

15:30 Coffee Break

16:00

The Boundaries of Written Description and Enablement: Lessons from Seagen v. Daiichi

On December 2, 2025, the US Court of Appeals for the Federal Circuit rendered a decision shaking the global ADC industry – holding Seagen’s U.S. Patent No. 10,808,039 invalid for lack of written description and enablement under 35 U.S.C. § 112, overturning a prior Texas jury verdict awarding Seagen US\$41.8 million in damages and ongoing royalties.

- Deep-dive review of the Seagen v. Daiichi case
- Far-reaching implications of US written description/enablement requirements for conjugate drug platform patents

 **Louis Fogel**
Principal
Fish & Richardson P.C.

16:30

Panel: Opportunities and IP Considerations for Chinese Pharma Going Global

China’s Pharma industry is now at a strategic gateway for global expansion. From the record-high 2025 total out-licensing value exceeding US\$135.6 billion to the Q1 2026 transaction value surpassing US\$57 billion, Chinese pharma companies are accelerating from “renting a boat” to “building their own boat” . This Panel brings together IP heads from biosimilar, generic and innovative pharma companies, as well as legal experts specialized in both Western and emerging markets, to discuss: in different therapeutic segments and different target markets, how can Chinese pharma use IP as both sword and shield to steadily navigate the global path?

 **Ying Zhang (chair)**
Founding Partner
IPSunny International Law

 **Lei Liu**
IP Head
Jiangsu Nhwa Pharmaceutical

 **Liming Sun**
IP Director
Qilu Pharmaceutical

 **Janet Xiao**
Partner
Morrison & Foerster LLP

 **Luis Maciel**
Partner
DANIEL

 **Yuan Zhang**
Deputy IP Director
Hengrui Pharma

18:00

End of Pre-Conference Seminars

 18:10
Cocktail Reception
Dragon Ballroom B, 6F (Open to all participants)

Pre-Conference Seminar F
IP Sunny International Law Dedicated Session (Comparative study of PTE)

 **Dr. Yongmei Gong (Chair)**
Sr. Partner
IP Sunny International Law

14:00

Current Status and Prospects of Pharmaceutical PTE in China

 **Xiarui Dou**
Sr. Partner
IP Sunny International Law

14:30

SPCs in Europe: Scope, Challenge, and the Path to Generic Entry

 **Cristina Biggi**
Partner
Bugnion S.p.A.

15:00

Applying Legacy Statutes to Modern Modalities: Adapting US PTE Law for Complex Biologics

 **Jean Ge**
US Patent Attorney
Wolf, Greenfield & Sacks, P.C.

15:30

Coffee Break

16:00

Practice and Strategies of the Patent Term Extension (PTE) System in Japan: Multiple Extensions, Scope of Rights, and Recent Trends

 **Sayaka Ueno**
Attorney
TMI Associates

16:30

Korean PTE Practice and Recent Case Law

 **Ara Cho**
Partner
Lee International IP & Law

17:00

End of Pre-Conference Seminars

 18:10
Cocktail Reception
Dragon Ballroom B, 6F (Open to all participants)

 **Yongshun Cheng** (Chair)
Former Deputy Head of IP Division
Beijing High People's Court

07:30 大会签到

8:50
Opening Remarks

 **Qingkui Zhang**
Honorary Director
Pharma IP Right Research Committee of Chinese
Pharmaceutical Association

9:00
Judicial Review Perspectives on the
Interpretation and Application of Patent Term
Compensation Provisions for New Drug
Inventions in China

 **Dr. Qinghui Liu**
Partner
Anjie Broad

9:30
Pharma IP Challenges in the New Landscape
of BD, NewCo, Out-Licensing, and Generic-
Innovator Dynamics

 **Weibin WANG**
Senior Partner
Beshining law firm

10:00
System of Patent Term Compensation for New
Drugs in China

 **Li Wu**
Partner
Lifang & Partners

10:30 Coffee Break

11:00
Impact of 2025-2026 Biopharma Reexamina-
tion and Invalidation Case Dynamics on
Patent Drafting and Portfolio Strategy

 **Yibo He**
Partner
FAIRSKY Law Office

11:30
Panel: Judicial Protection - Observations
and Trends from Retrial and Pending Cases
on Patent Linkage and Patent Term Extension

Drug patent linkage and term extension are both “moats” for innovative pharma and “breach points” for generics. In recent years, the Beijing IP Court and the Supreme People’s Court have heard (or are hearing) a series of landmark cases, forming adjudicative rules on issues such as patent linkage litigation, admissibility of supplementary experimental data, and the scope of PTE application. This Panel will review typical cases and discuss the profound implications of judicial practice for industry IP strategies.

 **Yongshun Cheng** (Chair)
Former Deputy Head of IP Division
Beijing High People's Court

 **Zhefeng Chen**
Deputy General Manager of Chemical,
Pharmaceutical and Biological Division
SHANGHAI PATENT & TRADEMARK LAW OFFICE, LLC

 **Dr. Wenjun Geng**
VP
CTTQ

 **Tony Chen**
Partner
Jones Day

12:40 Buffet Lunch (2F ,O2on2)

 **Tony Chen** (Chair)
Partner
Jones Day

14:00
The Evolution of STN—How CAS IP Finder
Delivers Strategic IP Intelligence for
Pharmaceutical Innovation

 **Dr. Kaiqian Chen**
Customer Success Specialist
CAS

14:30
Research on pharmaceutical polymorphs
and patent protection

 **Xian Du**
Patent Agent
CCPIT PATENT AND TRADEMARK LAW OFFICE

15:00
Patentability Requirements and Protection
Scope of Crystalline Form Inventions in Korea

In recent years, the Korean Supreme Court has rendered a series of decisions relaxing the patentability standards for crystalline form inventions, particularly the inventive step requirement, making such patents progressively easier to obtain in Korea. In its 2026 decisions, however, the Court applied considerably stricter standards to the specifica- tion disclosure requirements and the scope of protection under the doctrine of equivalents. This presentation reviews the Court's reasoning and explores strategies for both obtaining and enforcing patent protection for crystalline form inventions in Korea.

 **Ilseok Alban Kang**
Patent Attorney
FirstLaw P. C.

15:30 Coffee Break

16:00
Fireside Chat with UPC Judges: Trends in
Pharma Case Adjudication at the Unified
Patent Court

Amgen v. Sanofi: the UPC Court of Appeal reversed a first-instance revocation decision, establishing standards for inventive step review; Abbott v. Sanuo: prelimi- nary injunction case highlighting long¶arm jurisdiction and procedural gamesmanship in emergency relief; Merz's first SPC preliminary injunction case set a time-limit red line for “un- reasonable delay” . With a dense output of 2025-2026 case law, UPC procedural rules are becoming increasingly clear. This fireside chat invites a UPC judge and a European lawyer to discuss cutting-edge trends and practical responses for biopharma patent protection.

 **Dr. Ulrich Storz** (Chair)
Senior Partner
Michalski Hüttermann & Partner

 **Edger Brinkman**
Presiding Judge
The Hague Local Division,
Unified Patent Court

16:40
Panel: Development Trends in Europe, UPC
and the US - How Pharma Companies Can
Prepare for the Future

- Cross-jurisdictional adaptability of patent drafting - how to cope with the diverging examination standards of EPO and USPTO?
- Biosimilar/BPCIA patent offense and defense - differences be- tween Europe and the US and predictions for 2027
- Global governance of “skinny label” and indirect infringe- ment - compliance boundaries
- Interaction between the UPC and national courts in Europe
- How should pharma companies plan their IP strategies for Europe and the US in 2027 - key points to watch

 **Dr. Mahendra Thakre** (Chair)
IP Vice President
VIATRIS (Mylan Laboratories
Limited)

 **Ping Cao**
Lead of Small Molecule IP, China
BeOne Medicines

 **Edger Brinkman**
Presiding Judge
The Hague Local Division,
Unified Patent Court

 **Bryce Matthewson**
Partner
Powell Gilbert LLP

18:00
End of Day 1



Dong Wei (Chair)

Deputy General Manager of Chemical,
Pharmaceutical and Biological Division

SHANGHAI PATENT & TRADEMARK LAW OFFICE, LLC

9:00

An Analysis of Preliminary Injunctions in Europe.

- what are the triggers?
- What factors are taken into consideration?
- Can it be cross-border?
- What if it’s wrongly granted?



Stella Wong

Partner

Hogan Lovells Cadwalader

09:30

The Next Step: How the UPC Assesses Inventive Step and Other Grounds of Invalidity



Dr. Lasse Weinmann

Partner

HOFFMANN EITLE



Dr. Elisabeth Engelhard

Partner

HOFFMANN EITLE

10:00

Hot Topics in US Patent Drafting and Prosecution – Patent Drafting, Examination and Post-Grant Review Trends

- New landscape for enablement and written description
- Latest rules for obviousness and obviousness-type double patenting (ODP)
- New rules for inventorship and disclosure of AI-assisted inventions
- New trends in PTAB/IPR proceedings



Peng Lin

Principal

Fish & Richardson P.C.

10:30 Coffee Break

11:00

Observations and Impact of US Pharma Patent Litigation

- Overview of US Pharma patent litigation
- Strategic collaboration within a joint defense group
- In re. Entresto: claim construction, trials, and appeals
- Hikma v. Amarin: the boundaries of skinny-label induced infringement
- Surge of BPCIA biosimilar litigation and challenges for Chinese pharma



Dr. Zhibin Li

Shareholder

Buchanan



Dr. Ling Zhong

Shareholder

Buchanan

11:30

Panel: Comparative Study of Equivalents in Drug Patent Infringement Cases – A China-US Judicial Perspective

Generics circumventing patents through non-substantial modifications – whether fast-follow drugs carry an equivalents risk – has become a common focus of attack and defense for both Chinese and US pharma companies. The application of the doctrine of equivalents directly affects the speed of generic market entry and the strength of innovative drug protection. In 2025-2026, China’s Supreme Court clarified that numerical parameters are not automatically excluded from equivalents, while the principle of estoppel is simultaneously tightened; the US Arbutus case defined a forbidden zone for equivalents claims, and the Hikma case placed “equivalence statements” under the microscope of induced infringement. Common modification practices for fast-follow molecules, such as isosteric replacement and configuration flipping, may all fall into the grey area of equivalents. This Panel will deeply dissect the adjudicative logic of equivalents in China and the US, seeking a balance in pharma patent offense and defense.



Yongfeng Zheng (Chair)

VP, Chief IP Officer

Tasly Pharma



Dr. Feng Xu

International Chief IP Counsel

AstraZeneca



Janet Xiao

Partner

Morrison & Foerster LLP



Buzhen Zhao

Partner

Hiways Law Firm



Songyan Rui

UPC Arbitrator, Mediator

Expert & WIPO Arbitrator, Mediator

12:40 Buffet Lunch (2F ,O2on2)

14:00

Brazil Pharma Patent Protection Practices and Latest Developments

Brazil is the largest Pharma market in Latin America, but drug patents are subject to the “dual examination” by BPTO and ANVISA, with serious backlogs. ADI #5529 drastically shortened patent terms, triggering a wave of PTA litigation. This session will analyze ANVISA’s new rules, PTA litigation strategies, and generic challenge practices, helping Chinese pharma break through Brazil’s market access barriers.



Ricardo Campello

Partner

Licks Attorneys

14:30

Compulsory license court CASE STUDY in Russia and Eurasia



SERGEY ZUYKOV

Managing Partner

ZUYKOV

15:00 Coffee Break

15:30

Panel: How Chinese Pharma Companies Can Build an MMC (MNC)-Minded IP System

In Q1 2026, China’s innovative drug out-licensing reached over US\$5.7 billion in total value, and first-quarter deals already exceeded the full-year 2024 level. License-out has moved from “occasional big ticket” to “regularized outbound” . Companies like Baili Tianheng have articulated the strategic goal of “rooted in China, going global, becoming an MNC” , while Hengrui is exploring internationalization through multiple parallel pathways. Chinese pharma is accelerating from “renting a boat” to “building its own boat” . This Panel will bring together IP heads from both MNCs and Chinese pharma to discuss how to build a globalized IP system.



Weibin WANG (Chair)

Senior Partner

Beshining law firm



Sunny Wang

CEO

SR Biomedical



Steven Cui

Head of IP,China/Asia

Bristol-Myers Squibb



Songxi Guo

China IP Head

Astellas (China) Investment

16:30

Panel: Comparative Analysis of Examination and Authorization Standards for Pharma Patents in China, the US and Europe


- Differences in inventive step (obviousness) examination
- Differences in novelty examination
- Differences in insufficient disclosure (enablement/written description) examination



Qingkui Zhang (Chair)

Honorary Director

Pharma IP Right Research Committee of Chinese Pharmaceutical Association



Caihui Li

Deputy General Manager of IP

Junshi Biosciences (Junshi Venture Capital, Partner, Jingsheng Capital)



Aiyao Zhan

IP Director

Hangzhou Bio-Sincerity Pharma-Tech



Guiming Liu

Former Second Level Inspector and Director of the Ministry of Chemistry

Patent Office of the China National IP Administration

17:30 End of Conference